NCT04856865已完成1 期
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Harmony Study)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 73
- 试验地点
- 16
- 主要终点
- 600mg Desensitization in at Least One Qualifying Food
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
详细描述
This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of ADP101 for oral immunotherapy in food allergic children and adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 4 Years 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 4 to 55 (inclusive)
- •Clinical history of allergy to at least 1 of the foods contained in ADP101
- •Experience dose-limiting symptoms at or below the 100-mg dose level to 1 or multiple food sources in ADP101
排除标准
- •Experience dose limiting symptoms at or below the 100 mg challenge dose level to more than 5 food sources contained in ADP101
- •History of severe or life-threatening episode(s) of anaphylaxis or anaphylactic shock within 60 days of screening
- •History of EoE, other eosinophilic gastrointestinal disease, chronic, recurrent or severe GERD, symptoms of dysphagia
- •Severe asthma
- •Mild or moderate asthma, if uncontrolled or difficult to control
- •History of mast cell disorder, including mastocytosis, urticaria pigmentosa or angioedema
- •History of chronic disease (other than asthma, atopic dermatitis, or allergic rhinitis) at risk of becoming unstable or requiring a change in chronic therapeutic regimen e.g. uncontrolled diabetes
- •History of cardiovascular disease, including hypertension requiring > 2 antihypertensive medications
- •History of interstitial lung disease
- •History of celiac disease
- •Active autoimmune disease that has required systemic treatment within 3 months
- •Known malignancy that is progressing or has required active treatment within the past 3 years
- •Known history of HIV, known active hepatitis B infection or known active hepatitis C virus infection
- •Prior/concurrent therapies as follows:
- •beta-blockers, ACE inhibitors, ARBs or calcium channel blockers
- •regular steroid medication use
- •therapeutic antibody treatment currently or within the previous 6 months
- •any food immunotherapy currently or within the previous 12 weeks
- •In the build up phase of non-food immunotherapy
- •Residing at the same address as another subject (e.g. siblings) participating in this or any other OIT study
- •Develops dose-limiting symptoms to placebo during the Screening DBPCFC
- •Any other condition that might preclude safe participation in the study
结局指标
主要结局
600mg Desensitization in at Least One Qualifying Food
时间窗: 40 Weeks
The proportion of participants in the pediatric ITT population who tolerated the 600mg level of a single qualifying food without dose limiting symptoms at the Week 40 Exit DBPCFC.
次要结局
- 1000mg Desensitization Threshold, Multi-allergic Pediatric ITT Population(40 Weeks)
- 600mg Desensitization Threshold, Multi-allergic Pediatric ITT Population(40 weeks)
- 1000mg Desensitization Threshold in Pediatric ITT Population(40 weeks)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
3 期
Peanut Oral Immunotherapy Study of Early Intervention for DesensitizationPeanut AllergyNCT03736447Aimmune Therapeutics, Inc.146
已完成
1 期
Sublingual Immunotherapy Studies for Grass and Dust Mite AllergiesAllergiesAllergic RhinitisAsthmaNCT01529437Stanford University31
已完成
1 期
Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental ChamberAllergic RhinitisNCT00836914Gilead Sciences41
已完成
3 期
PALISADE Follow-on Study (ARC004)Peanut AllergyNCT02993107Aimmune Therapeutics, Inc.388
终止
3 期
A Study of 2 Doses of MAP0010 in Asthmatic ChildrenAsthmaNCT00697697Allergan192